Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Compagnie Lombard Odier SCmA

Compagnie Lombard Odier SCmA boosted its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) by 286.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,245 shares of the biotechnology company's stock after buying an additional 15,000 shares during the quarter. Compagnie Lombard Odier SCmA's holdings in Viking Therapeutics were worth $489,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in VKTX. Wesbanco Bank Inc. raised its stake in shares of Viking Therapeutics by 101.7% during the first quarter. Wesbanco Bank Inc. now owns 23,800 shares of the biotechnology company's stock valued at $575,000 after acquiring an additional 12,000 shares in the last quarter. Principia Wealth Advisory LLC raised its position in Viking Therapeutics by 10.5% during the 1st quarter. Principia Wealth Advisory LLC now owns 6,478 shares of the biotechnology company's stock valued at $150,000 after purchasing an additional 616 shares in the last quarter. RFG Advisory LLC bought a new stake in Viking Therapeutics during the 1st quarter valued at $958,000. NBC Securities Inc. lifted its holdings in shares of Viking Therapeutics by 222,100.0% in the 1st quarter. NBC Securities Inc. now owns 2,222 shares of the biotechnology company's stock worth $53,000 after buying an additional 2,221 shares during the period. Finally, Future Financial Wealth Managment LLC increased its stake in shares of Viking Therapeutics by 1,242.9% during the first quarter. Future Financial Wealth Managment LLC now owns 2,350 shares of the biotechnology company's stock valued at $57,000 after buying an additional 2,175 shares during the period. 76.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts have issued reports on VKTX shares. Morgan Stanley dropped their target price on shares of Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. HC Wainwright reiterated a "buy" rating and set a $102.00 price objective on shares of Viking Therapeutics in a research note on Thursday, April 24th. Truist Financial reissued a "buy" rating and issued a $75.00 price objective (down previously from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. The Goldman Sachs Group started coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 target price on the stock. Finally, Scotiabank assumed coverage on Viking Therapeutics in a report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, Viking Therapeutics has an average rating of "Moderate Buy" and an average price target of $87.15.

Insiders Place Their Bets

In other Viking Therapeutics news, Director Sarah Kathryn Rouan acquired 1,240 shares of the firm's stock in a transaction on Monday, March 31st. The stock was acquired at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the purchase, the director now owns 1,240 shares in the company, valued at approximately $29,946. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.10% of the stock is currently owned by insiders.

Viking Therapeutics Stock Performance

VKTX stock traded down $2.50 during trading on Friday, reaching $26.08. The company had a trading volume of 6,079,091 shares, compared to its average volume of 4,068,641. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -26.08 and a beta of 0.65. Viking Therapeutics, Inc. has a twelve month low of $18.92 and a twelve month high of $81.73. The firm has a 50-day simple moving average of $26.34 and a 200-day simple moving average of $32.37.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm's revenue was up .0% compared to the same quarter last year. During the same period last year, the business posted ($0.26) EPS. Sell-side analysts expect that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.